^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    WSB2 expression

    i
    Other names: WSB2, WD Repeat And SOCS Box Containing 2, WD Repeat And SOCS Box-Containing Protein 2, CS Box-Containing WD Protein, WSB-2, SBA2, WD Repeat And SOCS Box-Containing 2, MGC10210
    Entrez ID:
    55884
    Related biomarkers:
    Expression
    12ms
    Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma. (PubMed, Exp Mol Med)
    Targeting mTOR with everolimus, an oral drug, significantly blocked WSB2-triggered HCC tumorigenesis and metastasis in vivo. In clinical samples, high expression of WSB2 was associated with low wild-type p53 expression and high p-mTOR expression. These findings demonstrate that WSB2 is overexpressed and degrades wild-type p53 and then activates the IGFBP3-AKT/mTOR axis, leading to HCC tumorigenesis and lung metastasis, which indicates that targeting mTOR could be a new therapeutic strategy for HCC patients with high WSB2 expression and wild-type p53.
    Journal
    |
    TP53 (Tumor protein P53) • mTOR (Mechanistic target of rapamycin kinase) • IGFBP3 (Insulin-like growth factor binding protein 3) • WSB2 (WD Repeat And SOCS Box Containing 2)
    |
    TP53 wild-type • TP53 expression • WSB2 expression
    |
    everolimus